Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.
about
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingIntratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer.Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35Decreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.In-vitro effect of pembrolizumab on different T regulatory cell subsets.Tissue-specific Differences in Immune Cell Subsets Located in the Naso-oropharyngeal-associated Lymphoid Tissues.CD137+CD154- Expression As a Regulatory T Cell (Treg)-Specific Activation Signature for Identification and Sorting of Stable Human Tregs from In Vitro Expansion Cultures.Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.The Effects of Anti-LAP Monoclonal Antibody Down-regulation of CD4+LAP+ T Cells on Allogeneic Corneal Transplantation in Mice.Immune oncology, immune responsiveness and the theory of everything.Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
P2860
Q26742012-37241CFB-3B0D-4143-BCA5-CD508E665F02Q33729278-F58574F0-7617-4989-92E4-E438A3D88317Q33779401-FECF4975-330A-4060-A8A7-CCB573328891Q33822472-D1AF6659-959F-43FF-ABA7-349E428AE88AQ37020109-CF495B7B-B6C0-4F4B-B234-F2782DEEB31BQ37706835-66E8C601-3DFE-461A-821C-63C4E5260E7FQ47616276-31C59F9B-ABDB-4687-8372-D1D1040B10D8Q48113470-DA5D2117-BE48-49A8-B176-8F8398C010A4Q50281162-BA57D2C3-A9C9-4B77-A9D1-1745554F5A30Q50545420-BCF090C6-2049-4111-BDC1-6871974BAE42Q55005463-9234A1D5-207A-47A1-84D9-698D7CE31921Q55487467-5070C629-A413-446B-9645-3602A47046B5Q56888845-74250E17-A86A-492E-9EF0-568C968D34D3
P2860
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combining FoxP3 and Helios wit ...... eg subsets in cancer patients.
@en
Combining FoxP3 and Helios wit ...... eg subsets in cancer patients.
@nl
type
label
Combining FoxP3 and Helios wit ...... eg subsets in cancer patients.
@en
Combining FoxP3 and Helios wit ...... eg subsets in cancer patients.
@nl
prefLabel
Combining FoxP3 and Helios wit ...... eg subsets in cancer patients.
@en
Combining FoxP3 and Helios wit ...... eg subsets in cancer patients.
@nl
P2860
P50
P356
P1433
P1476
Combining FoxP3 and Helios wit ...... reg subsets in cancer patients
@en
P2093
Basil J Ammori
May Abd Al Samid
P2860
P304
14083-14094
P356
10.18632/ONCOTARGET.7334
P407
P577
2016-03-01T00:00:00Z